Originally published by our sister publication Clinical Oncology News
By Kate O'Rourke
The FDA has approved pembrolizumab (Keytruda, Merck) for adjuvant treatment following resection and platinum-based chemotherapy for non-small cell lung cancer (NSCLC) stage IB (T2a ≥4 cm), II or IIIA.
Efficacy was evaluated in KEYNOTE-091, a multicenter, randomized, triple-blind, placebo-controlled trial. Patients had not received neoadjuvant radiotherapy or chemotherapy. They were randomized in a 1:1 fashion